CME

Faculty: Kathryn Arbour

Faculty: Eileen M. O'Reilly, MD

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

Faculty: Kathryn Arbour

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

Faculty: Eileen M. O'Reilly, MD

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

Faculty: Eileen M. O'Reilly, MD

Faculty: Kathryn Arbour

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

Faculty: Kathryn Arbour

Faculty: Eileen M. O'Reilly, MD

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

Host: Saurabh Malhotra, MD, MPH, FASNC

Faculty: Cigdem Akincioglu, MD, FASNC

Faculty: Kevin Alexander, MD

Faculty: Katherine Lee Chuy, MD

Faculty: Angela Dispenzieri, MD

Faculty: Sharmila Dorbala, MD, MPH, MASNC

Faculty: Cesia Gallegos-Kattán, MD, MHS, FASNC

Faculty: Wael Jaber, MD, FASNC

Faculty: Mike Lane

Faculty: Ahmad Masri, MD, MS

Faculty: Mathew S. Maurer, MD

Faculty: Frederick Ruberg, MD

Faculty: Prem Soman, MD, PhD, MASNC

Faculty: Brett Sperry, MD, FASNC

Faculty: Andrew Staron, MD

Faculty: Jonathan Wall, PhD

Faculty: Ashutosh Wechalekar, MBBS, MD

Faculty: David Wolinsky, MD, MASNC

Faculty: Sasha Zivkovic, MD, PhD

Faculty: A Sami Abuzaid, MD, FASNC

Faculty: Vasvi Singh, MD, FASNC

Faculty: Mark Hyun, CNMT, NCT, RS, RT(N,R,CT), FASNC

Faculty: Maria Mackin, BS, MS, CNMT, RT (N), LNMT, FASNC

Faculty: Ronald G. Schwartz, MD, MS, MASNC

The Masterclass in Cardiac Amyloidosis, 4-virtual 2.5 hr sessions, is focused on sharpening clinical skills in suspecting, diagnosing, treating, and longitudinally managing patients with ATTR cardiac amyloidosis.

ASNC will offer a focused 2-hour session for technologists titled, Amyloidosis for Technologists: Tips and Tricks from Experts on Saturday, March 14 from 1-3pm ET.

Faculty: Kevin J Harrington, PhD, FRCP, FRCR, FRSB

Faculty: Christophe Le Tourneau, MD, PhD

This online educational activity highlights cutting-edge clinical trial data shaping the future of care in both locally advanced and recurrent/metastatic HNSCC. Experts review novel approaches such as perioperative immunotherapy, radioenhancers in the definitive setting, and next-generation targeted therapies including bispecific antibodies in advanced disease. Faculty compare toxicity profiles across these strategies, emphasizing practical approaches to early adverse event recognition, prevention, and management. With a focus on real-world implementation, the program equips clinicians to translate investigational findings into informed treatment decisions and safer patient care.

Faculty: María-Victoria Mateos, MD, PhD

This expert lecture offers a focused review of the expanding role of bispecific antibodies earlier in the disease course of multiple myeloma. Learn about pivotal trial data with unprecedented efficacy that support this shift to use in early-line settings. Safety considerations, including infection risk and mitigation strategies, are addressed to guide real-world implementation. Together, these insights help clinicians optimize patient outcomes as bispecific antibodies move toward earlier integration in multiple myeloma care.

On March 5, 2026, the FDA approved teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

Faculty: Richard E. Pratley, MD

Faculty: David Cherney, MD, PhD

Faculty: prof. Hiddo Heerspink

Join Drs. Richard Pratley, David Cherney, and Hiddo Heerspink in this extended panel discussion, focused on results of the FINE-ONE clinical trial, which evaluated finerenone—a nonsteroidal mineralocorticoid receptor antagonist—in participants with type 1 diabetes and CKD. The dynamic conversation, which includes patient vignettes regarding the potential treatment implications, highlights the 25% albuminuria reduction demonstrated in FINE-ONE. Faculty underscores the use of albuminuria as a surrogate endpoint, and call for broader access and implementation of therapies shown to offer renal protection so that no patient is left behind when it comes to treatment for CKD.

Faculty: Jane Meisel, MD

This online educational activity, derived from a live Grand Rounds event, focuses on the application of molecular testing, evidence-based therapy selection, and interdisciplinary collaboration in the management of high-risk early-stage breast cancer (EBC) with germline BRCA mutations. In this chapterized activity, Dr. Jane Meisel reviews practical approaches for implementing guideline-directed BRCA testing and highlights disparities that impact equitable access to precision oncology. She also discusses the latest clinical evidence on adjuvant therapy for patients with high-risk EBC with germline BRCA mutations and uses a case-based learning lab to explore individualized adjuvant treatment strategies for these patients. The program also emphasizes proactive management of treatment-related adverse events, including patient counseling and coordinated supportive care, to optimize safety and adherence. Participants will gain practical strategies for integrating germline BRCA mutational status into treatment planning and for strengthening multidisciplinary care pathways, all in service of improving outcomes and reducing disparities for patients with high-risk EBC.